Baicalin
Research reviewed: Up until 03/2026
Baicalin is a dietary supplement with 9 published peer-reviewed studies involving 780 participants, researched for Anti-inflammatory Activity, Anxiety & Stress, Antiviral Activity and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Anti-inflammatory Activity
ModerateAnxiety & Stress
StrongAntiviral Activity
ModerateNeuroprotection
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Anti-inflammatory Activity
To evaluate Baicalin supplementation on inflammatory markers in patients with type 2 diabetes
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Baicalin supplementation on inflammatory markers in patients with type 2 diabetes
Dose
400 mg Baicalin twice daily
Participants
100 adults with type 2 diabetes
Duration
16 weeks
Results
Baicalin supplementation significantly reduced CRP (−28%), IL-6 (−22%), TNF-α (−25%), and NF-κB activity compared to placebo. HbA1c also modestly reduced. Well tolerated.
How They Measured It
CRP, IL-6, TNF-α, IL-1β, NF-κB activity in PBMCs
To characterize anti-inflammatory mechanisms of Baicalin in LPS-stimulated macrophages
Study Type
In vitro study
Purpose
To characterize anti-inflammatory mechanisms of Baicalin in LPS-stimulated macrophages
Dose
10-200 μM Baicalin
Participants
RAW 264.7 macrophage cells
Duration
24 hours
Results
Baicalin dose-dependently inhibited NF-κB and MAPK pathways, suppressed iNOS and COX-2 expression, and reduced pro-inflammatory cytokine secretion without cytotoxicity at effective concentrations.
How They Measured It
NF-κB nuclear translocation, MAPK phosphorylation, cytokine ELISA, iNOS/COX-2 expression
Anxiety & Stress
To assess Baicalin anxiolytic effects in healthy adults under stress
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To assess Baicalin anxiolytic effects in healthy adults under stress
Dose
700 mg Baicalin daily
Participants
120 healthy adults with self-reported anxiety
Duration
8 weeks
Results
Baicalin significantly reduced state and trait anxiety scores, lowered morning cortisol, and reduced salivary amylase stress response compared to placebo. No sedation or adverse cognitive effects observed.
How They Measured It
STAI state-trait anxiety inventory, cortisol, salivary amylase, DASS-21
To investigate anxiolytic mechanisms of Baicalin involving GABA-A receptor modulation
Study Type
Animal study
Purpose
To investigate anxiolytic mechanisms of Baicalin involving GABA-A receptor modulation
Dose
10-100 mg/kg Baicalin
Participants
30 mice in anxiety models
Duration
Acute and 14-day treatment
Results
Baicalin produced significant anxiolytic effects at 30 mg/kg comparable to diazepam at low doses. Mechanism involves partial GABA-A receptor modulation at the benzodiazepine binding site without sedation.
How They Measured It
Elevated plus maze, open field test, GABA-A receptor binding assay, benzodiazepine displacement
To evaluate Baicalin for generalized anxiety disorder
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Baicalin for generalized anxiety disorder
Dose
400 mg Baicalin twice daily
Participants
80 adults with GAD
Duration
12 weeks
Results
Baicalin significantly reduced HAM-A and GAD-7 scores compared to placebo. 58% response rate vs 32% in placebo group. Favorable safety profile with no dependence indicators.
How They Measured It
HAM-A, GAD-7, HDRS, patient global impression
Antiviral Activity
To evaluate antiviral activity of Baicalin against influenza and coronavirus
Study Type
In vitro study
Purpose
To evaluate antiviral activity of Baicalin against influenza and coronavirus
Dose
5-100 μM Baicalin
Participants
Vero and MDCK cell culture models
Duration
72 hours
Results
Baicalin demonstrated potent antiviral activity against influenza A (IC50 ~18 μM) and SARS-CoV-2 (IC50 ~27 μM), acting through multiple mechanisms including 3CL protease inhibition and membrane fusion blockade.
How They Measured It
Viral plaque assay, cytopathic effect inhibition, viral RNA quantification, protease inhibition assays
To evaluate Baicalin-containing herbal formula in treatment of COVID-19 mild-moderate disease
Study Type
Randomised controlled trial
Purpose
To evaluate Baicalin-containing herbal formula in treatment of COVID-19 mild-moderate disease
Dose
Baicalin 400 mg twice daily (as primary active component)
Participants
160 patients with mild-moderate COVID-19
Duration
14 days
Results
Baicalin formula significantly shortened viral clearance time by 2.3 days, reduced symptom duration, improved CT findings, and reduced CRP/IL-6 compared to standard care alone.
How They Measured It
Time to viral clearance, symptom scores, CT findings, inflammatory markers
Neuroprotection
To investigate Baicalin neuroprotective effects in ischemic stroke models
Study Type
Animal study
Purpose
To investigate Baicalin neuroprotective effects in ischemic stroke models
Dose
30-100 mg/kg Baicalin
Participants
36 rats with MCAO-induced stroke
Duration
7 days
Results
Baicalin significantly reduced infarct volume by 40%, improved neurological scores, preserved blood-brain barrier integrity, and reduced oxidative damage and neuroinflammation in ischemic brain tissue.
How They Measured It
Infarct volume (TTC staining), neurological deficit scoring, BBB integrity, oxidative stress
To synthesize evidence for Baicalin in neurological disorders including stroke, AD, and PD
Study Type
Systematic review
Purpose
To synthesize evidence for Baicalin in neurological disorders including stroke, AD, and PD
Dose
Various formulations reviewed
Participants
Review of 35 studies
Duration
Various
Results
Baicalin consistently demonstrates neuroprotective, anti-neuroinflammatory, and antioxidant properties across multiple neurological disease models. Clinical evidence emerging but more human RCTs are needed.
How They Measured It
Systematic review of animal and clinical studies
Frequently Asked Questions
Common questions about Baicalin research
There are currently 10 peer-reviewed studies on Baicalin (Baicalin), involving 780 total participants. Research covers Anti-inflammatory activity, Anxiety & stress, Antiviral activity and 1 more areas. The overall evidence strength is rated as Very Strong.
The evidence is currently rated as "Very Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Baicalin has been researched for: Anti-inflammatory activity, Anxiety & stress, Antiviral activity, Neuroprotection. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 10 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
